Cannabis
113
19
28
59
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
17 trials with published results (15%)
Research Maturity
59 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.9%
1 terminated out of 113 trials
98.3%
+11.8% vs benchmark
4%
4 trials in Phase 3/4
29%
17 of 59 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 59 completed trials
Clinical Trials (113)
Improving Pain Disability With the Use of Oral Cannabinoids
Delta-8-THC vs. Delta-9-THC on Simulated Driving Performance
Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users
Developing and Strengthening Cannabis Warnings: Warning Message Testing
Repeated CBD Administration and Cannabis Outcomes
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4
Allergenic Risk Assessment of Hemp Seed
The Pharmacokinetics of a Hemp-Based Topical Product
Nicotine and Cannabis Vape Labeling Experiment - Spring 2025
Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3
Study on Regulated Cannabis Sales in Pharmacies
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I
Cannabinoids, Learning, and Memory
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
Reducing Breathlessness With Dronabinol in COPD Patients